ClinicalTrials.Veeva

Menu

A Real-World Study of Bispecific Antibodies in Multiple Myeloma (BISPEMM)

A

Assistance Publique - Hôpitaux de Paris

Status

Completed

Conditions

Multiple Myeloma

Treatments

Other: Treated by bispecific antibodies, teclistamab or elranatamab in usual care
Other: Not treated by bispecific antibodies in usual care

Study type

Observational

Funder types

Other

Identifiers

NCT06359067
APHP240295

Details and patient eligibility

About

Bispecific antibody (BsAb) treatments, teclistamab and elranatamab, are newly available for patients with multiple myeloma who are refractory to all current drugs. The results are very encouraging but complicated adverse events, particularly infectious. This study analyzes survival data in patients treated with BsAb, as well as safety data, in particular the proportions and locations of infectious events. The results are compared to a control cohort. This study is multicentric on all the university hospitals of Paris (AP-HP).

Full description

Bispecific antibody (BsAb) treatments, teclistamab and elranatamab, are newly available for patients with multiple myeloma who are refractory to all current drugs. The results are very encouraging but complicated adverse events, particularly infectious. This study analyzes survival data in patients treated with BsAb, as well as safety data, in particular the proportions and locations of infectious events. The results are compared to a control cohort. This study is multicentric on all the university hospitals of Paris (AP-HP).

Enrollment

600 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult ≥ 18 years old
  • Patients with multiple myeloma
  • Patients who received at least one administration of the following therapies: teclistamab, elranatamab

Exclusion criteria

  • Patients opposed to the collection of their personal data

Trial design

600 participants in 2 patient groups

Treated by bispecific antibodies
Description:
Patients with multiple myeloma, penta-drug or triple class refractory and treated by bispecific antibodies, teclistamab or elranatamab
Treatment:
Other: Treated by bispecific antibodies, teclistamab or elranatamab in usual care
Control group
Description:
Patients with multiple myeloma, penta-drug or triple class refractory and not treated by bispecific antibodies
Treatment:
Other: Not treated by bispecific antibodies in usual care

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems